|
|
Vaccine Detail
|
MDX-CTLA4 Antibody/Tyrosinase/gp100/MART-1 Melanoma Vaccine |
| Vaccine Information |
- Vaccine Name: MDX-CTLA4 Antibody/Tyrosinase/gp100/MART-1 Melanoma Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Cocktail vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Antigen: tyrosinase 368-376 (370D); gp100 209-217 (210M); and MART-1 26-35 (27L) (NCT00028431)
- Immunization Route: Intravenous injection (i.v.)
- Description: This melanoma vaccine chemotherapy cocktail is composed of CTLA-4 antibody; tyrosinase, gp100, and MART-1 peptides; and incomplete Freund's adjuvant (IFA) with or without interleukin-12 in patients with resected stage III or IV melanoma. (NCT00028431)
|
| Host Response |
|
|
| References |
NCT00028431: Novel Adjuvants for Peptide-Based Melanoma Vaccines [https://clinicaltrials.gov/study/NCT00028431]
|
|
